First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: A meta-analysis

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Jiang, Yiwei ^a   Yin, Wenjin ^b   Zhou, Liheng ^b   Yan, Tingting ^a   Zhou, Qiong ^a   Du, Yueyao ^a   Shen, Zhenzhou ^b   Shao, Zhimin ^b   Lu, Jinsong ^b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; HER2 PROTEIN, HUMAN; TAXOID;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; EARLY CANCER; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE; METABOLISM; METHODOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; STATISTICAL ANALYSIS; TIME; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DATA INTERPRETATION, STATISTICAL; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; SALVAGE THERAPY; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863247417     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032474     Document Type: Article

References (25)

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
2. Arcamone F, Bernardi L, Patelli B, Giardino P, Di Marco A, et al. (1978) Synthesis and antitumour activity of new daunorubicin and adriamycin analogues. Experientia 34: 1255-1257.
3. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, et al. (2009) Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol 10: 1145-1151.
4. Poole C, (2004) Adjuvant chemotherapy for early-stage breast cancer: the tAnGo trial. Oncology (Williston Park) 18: 23-26.
5. Kaye SB, (1998) New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 78 (Suppl 3): 1-7.
6. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, et al. (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019.
7. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823.
8. Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, et al. (2009) NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 7: 1060-1096.
9. Joensuu H, Kellokumpu-Lehtinen P-L, Huovinen R, Jukkola-Vuorinen A, Tanner M, et al. FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast Cancer; 2010 December 8-12; San Antonio, TX. Cancer Res Abstract nr S4-1.
10. O'Shaughnessy J, Paul D, Stokoe C, Pippen J Jr, Blum JL, et al. First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer; 2010; San Antonio, TX. Cancer Res Abstract nr S4-2.
11. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, et al. (2012) Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol 30: 11-18.
12. Moreno-Aspitia A, Perez EA, (2009) Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 31: 1619-1640.
13. Campone M, Fumoleau P, Bourbouloux E, Kerbrat P, Roche H, (2005) Taxanes in adjuvant breast cancer setting: which standard in Europe? Crit Rev Oncol Hematol 55: 167-175.
14. Kurosumi M, Tabei T, Suemasu K, Inoue K, Kusawake T, et al. (2000) Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 7: 945-948.
15. Fujimoto-Ouchi K, Tanaka Y, Tominaga T, (2001) Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 7: 1079-1086.
16. Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, et al. (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12: 1247-1254.
17. Steger GG, Greil R, Jakesz R, Lang A, Mlineritsch B, et al. Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC); 2010 June 4-8; Chicago, Illinois. J Clin Oncol abstr 530.
18. Lin Y, Yin W, Yan T, Zhou L, Di G, et al. (2009) Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. BMC Cancer 9: 342.
19. Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, et al. (2009) Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 115: 325-333.
20. De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, et al. (2010) Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 36 (Suppl 3): S80-86.
21. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, et al. (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357: 1496-1506.
22. Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, et al. (2010) Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol 28: 2958-2965.
23. Martin M, Segui MA, Anton A, Ruiz A, Ramos M, et al. (2010) Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363: 2200-2210.
24. Morales S, Lorenzo A, Ramos M, Ballesteros P, Mendez M, et al. (2004) Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study. Cancer Chemother Pharmacol 53: 75-81.
25. Airoldi M, Cattel L, Pedani F, Marchionatti S, Tagini V, et al. (2001) Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. Breast Cancer Res Treat 70: 185-195.